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Abstract The case for continued follow-up of existing
cohorts arises from the key attributes of cohorts that are
already meeting the goals proposed by Potter for the cre-
ation of a new cohort. These attributes include the basic
nature of ongoing cohorts in that they are, by design,
hypothesis-driven and must adapt to emerging technologies
over time. Importantly, cohort investigators must identify
and address gaps in knowledge that will inform public
health strategies and clinical practices. Above all, cohorts
must capitalize on their unique features to address public
health priorities and inform our prevention strategies.
Continued follow-up adds substantial return on investment
to guide cancer prevention.
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The case for continued funding of cohorts has been made in
part through previous commentaries [1, 2], and in contrast,
Potter has called for the creation of a new ‘‘last cohort’’
[3, 4]. Such a last cohort or large-scale human observational
study would include genetics, environment, early-detection
markers, molecular classiﬁcation of outcome, and treatment
data to inform clinical practice [3], in fact replicating the
existing cohort studies that together follow 4 million men
and women (in 39 cohorts), with over 2 million having
germline DNA blood samples stored [5]. Potter indicated
that a new cohort focused on the collection of fresh tissue
from incident cancer cases should take precedence over
continuing the funding of existing cohorts and the inefﬁ-
cient and piecemeal addition of tumor samples to these
cohorts [4]. Such fresh tissue would help reduce outcome
heterogeneity. Furthermore, in 2005, he argued that cases
should be followed to evaluate outcomes and to address
survivorship issues; an approach we adopted in the Nurses’
Health Study in 1992 by adding quality of life assessment
and follow-up of breast cancer cases with subsequent
funding to evaluate outcomes (R01AG014742, GAC PI).
Here, I build the case for continued follow-up focusing on
key attributes of cohorts that are already meeting the goals
proposed by Potter for a new cohort and provide a greater
return on investment than starting a new ‘‘last cohort’’.
These include the basic nature of ongoing cohorts in that
they are, by design, hypothesis-driven and must adapt to
emerging technologies over time. Importantly, cohort
investigators must identify and address gaps in knowledge
that will inform public health strategies and clinical prac-
tices. Above all, cohorts must capitalize on their unique
features to address public health priorities and inform our
prevention strategies.
Hypothesis-driven cohorts
While it is given that cohorts such as other NIH-funded
research endeavors must be hypothesis-driven, it is instruc-
tive to brieﬂy review the origin of several major cohorts
that have helped shape public health in the United States
and internationally. Take for example the American Cancer
Society cohort studies, which have documented the major
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basis for CDC projects and global estimates of the burden
of tobacco [6]. The British Doctors Study likewise con-
ﬁrmed with a prospective design the original ﬁndings of
Doll [7, 8] relating smoking to excess lung cancer and
other conditions.
The Nurses’ Health Study, on the other hand, was
established to address the potential relation between use of
oral contraceptives and breast cancer and to evaluate
relations between smoking and cancer, extending ﬁndings
to women [9]. The Health Professionals Follow-up Study
was ﬁrst funded to address dietary etiologies of coronary
heart disease [10] but then moved to NCI-based funding
with a focus on cancer [11]. Other cohorts have been
established to address cancer in speciﬁc race and ethnic
groups: Multiethnic Cohort [12], Black Women’s Health
Study [13] and the Southern Cohort [14] and speciﬁc
occupations such as the Agricultural Health Study [15].
Adapting technology
Numerous examples attest to the adaptive design, devel-
opment and application of new technologies to further
understanding of disease etiology and potential for pre-
vention. Examples range from development and validation
of dietary assessment methods for large population studies
[16] to collection of blood samples from tens of thousands
of study participants [17, 18], collection of tissue blocks to
provide more detailed classiﬁcation of endpoints [19], and
assessment of lifestyle after diagnosis to document rela-
tions to cancer survival [20]. Adapting technology also has
reﬁned approaches to conduct cohort studies [21] and to the
uses that can be made of formalin-ﬁxed tissue to address
biologic mechanisms for exposure–disease relations [22].
Blood samples collected to address hypotheses relating
hormones to cancer risk [23] also served to provide DNA
for the evaluation of molecular markers [24] and ﬁnally to
contribute across numerous cohorts to studies of pathways
of potential importance in etiology of Breast and Prostate
Cancer (BPC3) [25] and then to genome-wide association
of SNPs and cancer [26].
Identifying gaps in knowledge
To fully address the role of lifestyle in cancer etiology and
prevention, we must understand when in the course of
disease exposure is most important. Examples from breast
cancer with the follow-up of survivors from the atomic
bomb in Japan attest to the value of cohort studies to deﬁne
the exposure–disease relation in the time course of life and
etiology [27]. Findings such as this also point to the need
for studies to address lifestyle during childhood and ado-
lescence in relation to breast cancer risk [28]. Cohorts
addressing diet, growth, and cancer risk work to ﬁll this
gap in knowledge [29, 30]. Follow-up of childhood cancer
survivors offers one important example of such cohort
ﬁndings relating to clinical practice guidelines [31]. On the
other hand, cohorts have been able to supplement existing
data resources to ﬁll in gaps in exposure over the life
course. For example, the validated measures of self-
reported body shape and adiposity [32] added to several
cohorts attest to the value of these measures in relation to
cancer risk [33]. Likewise, we added recall of high school
diet to the Nurses’ Health Study and then Nurses’ Health
Study II [34] and a more detailed assessment of physical
activity [35] to further reﬁne our ability to address ado-
lescent exposure and breast cancer risk [36, 37]. Validation
shows these measures can be included with adequate per-
formance to detect important relations. The California
Teachers Study took this approach from its beginning with
assessment of key exposures over the life course and
relating these exposures to risk of cancers [38–40].
Clearly in the setting of established data collection,
storage, and participant follow-up, the addition of data
collection strategies to ﬁll in periods of the life course that
may be particularly important offers a valuable and cost-
efﬁcient strategy to uncover details of exposure–disease
relations.
Understanding temporal details within exposure–disease
relations is essential to inform the timing and population
characteristics for prevention strategies. Cohort studies
have developed and validated measures of intermediate
endpoints such as colon polyps and benign breast lesions,
adding these endpoints to the existing cancer endpoints that
were of primary importance for initiating the cohort studies
[41]. With these endpoints, we can evaluate the timing of
diet and activity in relation to precursor lesions, progres-
sion to invasive disease, and progression from invasive
disease to recurrence and mortality.
Another approach to ﬁlling gaps in knowledge has been
the establishment of additional cohorts to address speciﬁc
populations. As noted above, these have often been deﬁned
by race or ethnicity or occupation. Another example relates
to adolescent exposure and the creation of the Growing Up
Today Study. Initial attempts to expand our assessment of
diet, physical activity, and growth in relation to subsequent
cancer risk were turned down as not innovative or lacking
validated measures of diet. With non-federal funds, I led
the creation and validation of the adolescent diet assess-
ment tool [42–44] prior to being awarded funds from
NICHD to study diet, adiposity, and excess weight gain for
gain in height among adolescent children of participants in
the Nurses’ Health Study II [45]. Again with the mother
already participating in the study, additional data sources
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little marginal cost.
Based on these examples, I conclude we should not
abandon existing cohorts to reallocate funds to the creation
of a new ﬁnal cohort.
Return on investment grows over time
Let me explain. The return on investment or sunk costs in
established cohorts is substantial, and return on this
investment grows over time. Numerous cohorts have added
collection of biologic samples to an extensive exposure
history and have added additional endpoints to maximize
the use of extensive exposure data collection and also allow
consideration of trade-offs between risks and beneﬁts of
components of lifestyle and other exposures. Furthermore,
to address the key question for informing prevention, we
must clearly document when in the time course of disease
an exposure is important for etiology, at what level of
exposure risk of cancer changes, and importantly, how
much exposure must change to reduce risk, how long that
change must be sustained to achieve a reduction in inci-
dence, and whether there is persisting protection after
cessation of exposure. (See Table 1.)
As an example, consider calcium intake and risk of
colon cancer. As Martinez and colleagues have elegantly
summarized, data from the pooling of prospective studies
of diet and cancer show that risk of colon cancer is elevated
at very low levels of intake. Risk declines with intake
increasing up to about 1,000 mg per day but then ﬂattens
with little further reduction in risk with greater intakes (see
Fig. 2 in Martinez et al. [48]). Conﬁrming this relation, the
Women’s Health Initiative randomized women who
already had intakes at baseline of approximately 1,151 mg
per day and observed minimal change in risk over 5 years
of supplementation [49]. Similar issues with the level of
intake among study participants also apply to the observed
lack of beneﬁt for vitamin D in this trial [49] (see Fig. 1).
Though not interpreted as consistent with the underlying
epidemiology by all reporters, these ﬁndings nevertheless
show the importance of key prevention questions in
deﬁning prevention strategies and the value in this case of
combined cohort data across many studies to deﬁne the
levels of exposure necessary to reduce risk.
The example of ‘‘ﬁlling in’’ exposure over the life
course to understand etiology as described above clearly
informs our understanding of exposure and disease etiol-
ogy. Expanding on this, we can consider the role of cohorts
in deﬁning exposure impacting on precursor lesions to a
greater (or lesser) extent than on invasive disease or even
lifestyle after disease onset and subsequent outcomes.
Numerous examples demonstrate these points. For exam-
ple, the availability of repeated measures of exposure
allows us to address change in exposure and change in risk
or sustained high exposure and achievable risk reduction.
For each of these questions, the cohort offers a broad set of
data that with further reﬁnement greatly adds to our
understanding and ultimately informs strategies for pre-
vention. Killing (or terminating) existing cohorts would be
an incredible waste of existing resources as we continue to
address the key question that will transform our population
level potential of cancer prevention into focused strategies
that achieve the goal of preventing more than half of all
cancers in Western societies.
Repeated measures inform prevention
Numerous components of lifestyle have been addressed
capitalizing on the availability of repeated measures in
cohort studies. Examples include smoking cessation and
continued non-smoking and the decline in incidence of
cancer [50]; aspirin and colon cancer [51]; weight loss and
breast cancer [52]; and methods development [53]—to
name just a few.
Consider aspirin and prevention of colon cancer. Clearly,
the time course matters. Epidemiologic data highlighted
Table 1 Questions to frame cancer prevention
Prevention questions Cohort Methods issues
Which exposure? Reﬁned measures Validation and error correction strategies
Change by how much? Observational cohorts ideally across
broad range of exposure
Consortium adds value of broader exposure
(e.g., EPIC and diet pooling project)
Among whom? At what age must
exposure be changed?
Level of exposure
Time course of exposure and disease
development
Consortium adds power to evaluate effects of age.
Intermediate endpoints reﬁne temporal relations
How long must change be
sustained?
Duration of altered exposure to modify
cancer incidence
Repeated assessment, updating exposure, reﬁned
measures of duration and continuing adherence
Does risk reduction persist after
cessation of exposure?
Updated exposure in cohort essential to
address this question
Follow-up of participants after intervention in trail
setting adds insights here too [46, 47]
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123the potential for prevention of colon cancer [51, 54], but
reﬁning this understanding required repeated measures and
intermediate endpoints. For example, in the Health Pro-
fessionals Follow-up Study, Chan and colleagues showed
that both dose and duration of exposure matters—observing
a 25% reduction in risk after 10 years of use and greater
reduction with higher dose [54]. Finally, the combined
analysis of randomized trials conﬁrmed these epidemiol-
ogic associations and demonstrated unequivocally that
beneﬁt is not observed until 10 or more years of use [55].
Additional endpoints
Even greater return on investment is achieved through
addition of endpoints for disease onset and for total mor-
tality [15, 56–58]. In each situation, one has the added value
of placing exposure–disease relation into a broader public
health context by potentially weighing risks and beneﬁts
across the multiple endpoints. While such approaches offer
challenges in some research settings, such as cancer-
speciﬁc research institutes and organizations, when other
chronic diseases have been added to cohorts, the gain in
understanding has been substantial with the marginal cost
limited to the documenting of the endpoints as question-
naire-based exposures are already collected and available.
An innovative resource that is added as a complement to
the California Teachers Study is the linkage to the Cali-
fornia hospital discharge databases (Ofﬁce of Statewide
Health and Planning), which has been validated as a
resource for multiple additional endpoints beyond cancer
[59]. The investigators thus have put in place permission
and systems to use this resource to capitalize on the cohort
to address a broader range of health issues, placing expo-
sure and outcomes for cancer in the context of other major
health events and also enriching the self-report data with
the history of gynecologic and other surgeries that may
modify cancer risk. This added resource has supported
discovery with publication of the ﬁrst paper on the epide-
miology and correlates of adenomyosis (a condition that,
although similar to endometriosis, affects the inner lining
of the uterus) [60]. They have also published on predictors
of surgery for endometriosis and ﬁbroids in the cohort [61].
As the added value of additional endpoints becomes more
widely recognized, other cohorts are linking to records for
identiﬁcation of non-cancer outcomes [62].
In summary, return on investment can be considered
through the gains as outlined above:
Understanding the time course of disease
Evaluating change in behavior and change in disease risk
Adding endpoints to evaluate the exposures in relation to
multiple diseases at low marginal cost and balancing
risks and beneﬁts of exposures/behaviors.
As I have emphasized in previous writing on cohorts
[1], maintaining high follow-up rates is key to internal
validity. This reﬂects, in part, the adaptive nature of
cohort studies. Use of web-based approaches to follow
participants, e-mail in addition to postal addresses, and
the like, attest to the adaptability of this design. In
addition, ongoing quality control measures are needed
within those cohorts that rely on tumor registry linkages
for conﬁrmation of incident cancers as performance of
linkages can vary over time.
Evaluating cohorts
Within the NCI Division of Cancer Control and Population
Sciences (DCCPS), increasing emphasis on evaluation of
major initiatives has placed led to new strategies to quan-
tify collaborative research [63]? Despite the overall con-
tribution of cohorts to cancer prevention, how does one
evaluate speciﬁc cohorts and potentially chose among them
for continued funding and follow-up? With Debbie Winn,
we proposed a set of metrics to evaluate large initiatives
such as cohorts within the NCI Division of Cancer Pre-
vention and Population Sciences [64]. These are summa-
rized below:
• Discovery
– To explain the etiology of diseases and health
conditions (e.g., journal articles, impact factors)
• Development
– To provide a basis for developing control measures
and prevention procedures for groups and popula-
tions at risk (e.g., determination of causes, public
health guidelines, risk models)
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Fig. 1 Vitamin D and colon cancer. Cohort data from Feskanich
et al. [64]
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123• Delivery
– Implementation, use of ﬁndings, evidence-based
public health policy and clinical guidelines (e.g.,
public awareness, policy applications)
While we applied these metrics to the Nurses’ Health
Study as an example in our original writing, application to
other cohorts conﬁrm the utility of these measures. For
example, under discovery metrics, including journal pub-
lications and the impact ranking of the journals, we showed
that publications during the ﬁrst 10 years of a cohort are
typically minor. In the Nurses’ Health Study, these were
largely cross-sectional studies and amounted to a total of
25 papers in the ﬁrst 10 years of follow-up [64]. Review of
the Childhood Cancer Survivor Study cohort [65] that
draws on a population of 14,000 5-year childhood cancer
survivors has endpoints arising far more rapidly than in an
etiology or primary prevention setting, yet still shows the
slow take-off in publications that reﬂect the time and
investment in establishing a cohort and the accompanying
methods for follow-up (see Fig. 2). During these ﬁrst
10 years, papers tend to be in discipline-speciﬁc journals
and high impact publications tend to develop as the cohort
matures. Of note, the CCSS has 44 percent of its publica-
tions through June 2009, in journals with impact factor of
10 or higher.
Development metrics ask that ﬁndings from cohorts
provide a basis for developing cancer control measures and
prevention procedures for groups and populations at risk
(e.g., determination of causes, public health guidelines, and
disease risk classiﬁcation models). Again, NHS-related
contributions are summarized previously [64]. Here, the
CCSS provides several examples that translate ongoing
ﬁndings from the follow-up of childhood cancers to pre-
vention/intervention strategies [65].
Delivery metrics include implementation, or use of ﬁnd-
ings, to guide evidence-based public health policy and
clinical guidelines or policy applications. The CCSS shows
thedirecttranslationoftheirﬁndingstoclinicalmanagement
guidelines, where the cohort has facilitated identiﬁcation of
childhood cancer survivor populations at high risk for spe-
ciﬁcorgantoxicityandsecondarycarcinogenesis,whichhas
directly informed clinical screening practices [66, 67].
Other applications of these metrics to cohorts support
their use for the evaluation of these studies. Publications
from GUTS, for example, follow the pattern of the NHS
and CCSS but with a stronger push for early publications to
sustain funding, and accordingly a number of papers in
leading discipline journals were published in the ﬁrst
5 years using prospective data as were methods papers
drawing on the cohort.
Closing cohorts
The lifespan of cohorts is not clear a priori—the British
Doctors Study has followed participants from the baseline
‘‘questionary’’ through 50 years [68]. Other cohorts are
continuing to mature, and some have ceased follow-up [6].
While individual cohorts may be evaluated against the
metrics of discovery, development, and delivery, we might
also consider the issues addressed under return on invest-
ment. The changing patterns of exposure, new populations
deﬁned by birth cohort, and immigration, all suggest that
from a public health perspective, NIH must balance a
portfolio of cohorts to adequately address lifestyle, occu-
pation, and other factors that are best evaluated through
long-term prospective cohort studies. Perhaps those cohorts
that are not best adapting to changing technologies and
understanding of disease processes and are not updating
exposure information after diagnosis (or similar factors
outlined under return on investment) should receive lower
priority for continued funding. Thus, in addition to the
evaluation of speciﬁc hypotheses for cohort competitive
renewal, we might also evaluate and score the contribution
to discovery, development and delivery and return on
investment to date, and the potential for return in the next
and 10 years should renewal funding be implemented.
Conclusion
In sum, cohorts are complex and most informative when
exposures are updated or multiple endpoints are addressed.
Most importantly for cancer etiology and prevention, they
can place exposure in the time course of disease develop-
ment to address key questions of timing and magnitude of
change necessary to result in prevention of cancer.
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123Furthermore, when multiple endpoints are addressed, they
can place etiology and prevention in broad public health
context giving insights to the trades-offs of risks and
beneﬁts of lifestyle and lifestyle changes. Established
modern cohorts clearly support numerous scientiﬁc inves-
tigations beyond the primary etiologic hypotheses deﬁned
to justify cohort follow-up. Based on these considerations,
it is clear that the return on investment of established
cohorts can increase over time, and careful consideration
should be given to the allocation of resources to maximize
the pay-off for informing prevention strategies.
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